Home › Compare › CPPCY vs ABBV
CPPCY yields 3.14% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, CPPCY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CPPCY + ABBV for your $10,000?
CP ALL Public Company Limited, together with its subsidiaries, operates and franchises convenience stores under the 7-Eleven name to other retailers primarily in Thailand. It operates through three segments: Wholesale Business, Retail Business, and Management of Rental Spaces in Shopping Centers. The Wholesale Business segment engages in import, export, and distribution of frozen and chilled food with delivery services and focuses on selling consumer products, including fresh food, dry food, and consumer products under Makro brand. Its Retail Business segment is involved in domestic supply chain, distribution system, logistics network, and brand equity businesses. This segment also sells its products under various domestic, international, and small and medium enterprises brands. The company's Management of Rental Spaces in Shopping Centers segment manages buildings and retail spaces in shopping malls. In addition, the company is involved in sale and maintenance of retail equipment; cash and carry, catalog, and e-commerce businesses; marketing and advertising activities; provision of information technology and research and development services, as well as engaged in bill payment collection, life insurance, and non-life insurance broker business. Further, the company offers educational institution, training, business seminar services, as well as healthcare and medical specialist's consultation services. As of December 31, 2021, CP ALL Public Company Limited operated 13,134 stores. The company was formerly known as C.P. Seven Eleven Public Company Limited. CP ALL Public Company Limited was founded in 1988 and is headquartered in Bangkok, Thailand.
Full CPPCY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.